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Abstract. Background: Imexon is an aziridine-containing
small pro-oxidant molecule with promising antitumor activity
in myeloma, lymphoma and lung and pancreatic cancer.
Imexon is already in clinical trials in patients with advanced
solid tumors. The present study examined the effects of
imexon on H9 and Raji lymphoma cell lines in vitro when
given in combination with ionizing radiation. Materials and
Methods: H9 and Raji lymphoma cells were grown in culture
and exposed to imexon, radiation, or both. Cells were
assessed for cell viability, glutathione content, induction of
apoptosis, cell cycle distribution and also subject to Western
blot analysis. Results: Imexon inhibited cell proliferation in
a dose-dependent manner. Imexon, given for 48 h prior to
irradiation at a clinically achievable dose of 40 μM, potently
enhanced the cell radiosensitivity. Imexon enhanced
radiation-induced apoptosis and accumulated cells in G2/M
phase of the cell cycle. Imexon induced caspase-3 activation
and PARP cleavage. Alterations in glutathione levels were
not observed at 40 μM of imexon. Conclusion: In conclusion,
imexon efficiently augmented lymphoma cell radiosensitivity
independently of glutathione and the underlying mechanisms
include induction of apoptosis and cell cycle redistribution. 
Imexon (4-imino-1,3-diazabicyclo-[3.1.0]hexan-one) is a 2-
cyanoaziridine-containing iminopyrrolidone (AmpliMed Co.,
AZ, USA) with in vitro and in vivo activity against a variety
of hematological and solid malignancies (1-5). In severe
combined immune-deficient (SCID) mice, imexon reduced
development of human lymphoma (6). Imexon was also active
against a murine tumor model bearing either P-388 or L-1210
leukemia (5). The mechanism of anticancer activity of imexon
is not completely understood. In the 1970s and 1980s, imexon
was under clinical development as a nonspecific
immunomodulatory agent for the treatment of cancer and
acquired immunodeficiency syndrome (AIDS) (7-9). In a study
using fresh human tumors in an in vitro tumor colony assay,
imexon showed selective toxicity against human myeloma with
an inhibitory concentration (IC50) of 0.2 μg/ml (10). Imexon
was subsequently investigated in preclinical myeloma models
for its capacity to modulate oxidative stress. In RPMI 8226
myeloma cells, Dvorakova et al. (11-13) showed that imexon at
concentrations between 90 μM and 500 μM induced apoptosis
mediated by formation of reactive oxygen species (ROS) and
reduced intracellular glutathione (GSH). Two recent studies
using the same RPMI 8226 myeloma model demonstrated
differential, concentration-dependent effects of imexon (14,
15). In these studies, low drug concentrations (below 180 μM)
induced apoptosis, necrosis or G2/M cell cycle arrest
independently of ROS and GSH levels. Of clinical relevance,
imexon is currently being explored for its potency to enhance
the effect of classic anticancer agents. Importantly, imexon was
active in dexamethasone- and chemotherapy-sensitive and -
resistant myeloma cell lines (14). In this study, significant
cytotoxicity was observed after 48-hour imexon incubation
(80-160 μM) in all cell lines in a time and dose-dependent
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manner. The mechanism of imexon cytotoxicity was induction
of apoptosis mediated by cleaved caspase 3. Moreover, some
but not all cell lines demonstrated caspase 8- and/or bcl2:bax-
dependent apoptosis. Another study evaluated the cytotoxic
effects of imexon in A375 human melanoma and RPMI 8226
myeloma cells when combined with a broad panel of
chemotherapeutic drugs (16). Imexon was synergistic when
combined with DNA-binding agents (cisplatin, dacarbazine,
melphalan) and pyrimidine-based antimetabolites (cytarabine,
fluorouracil, gemcitabine) in both cell lines. The authors
speculated that the synergy seen for imexon and alkylating
agents may relate to the thiol-dependent sulfhydryl-lowering
effect of imexon (17), which would render cells more sensitive
to electrophilic species from the alkylators (18). Imexon has
been shown to reduce stores of reduced sulfhydryls in RPMI
8226 myeloma cells exposed to high drug concentrations (11).
Interestingly, imexon exhibited an antagonistic effect when
combined with topoisomerase I and II inhibitors. The authors
attributed this antagonistic effect to potentially increased ROS
levels, which are known to antagonize the cytotoxic effects of
topoisomerase poisons (19). Together, these studies evoked our
interest to test the efficacy of imexon to radiosensitize tumor
cells. Because radiation, in addition to chemotherapy, is a
mainstay in the treatment of human lymphoma we investigated
the combined effects of imexon and radiation in two human
lymphoma cell lines. 
Materials and Methods
Reagents. Imexon used in this study was from Dr. Evan M. Hersh
(AmpliMed Co. AZ, USA). Cell culture media and penicillin-
streptomycin were from Invitrogen (Carlsbad, CA, USA). Fetal
bovine serum, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium
bromide (MTT), dimethyl sulfoxide (DMSO), and other chemicals
were from Sigma-Aldrich (St. Louis, MO, USA). 
Cell lines. Two human lymphoma cell lines, H9 (T-cell lymphoma)
and Raji (B-cell non-Hodgkin’s lymphoma), were used for the
study. The cells were grown in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal calf serum and with 1% penicillin-
streptomycin in a humidified atmosphere containing 5% CO2.
Proliferation assay. Cells were plated in 96-well plates and treated
the next day with different doses of imexon (10-160 μM). After 48
hours’ incubation, cells were stained with MTT, dissolved in
DMSO, and the absorbance was read at 540 nm using a 96-well
plate reader. 
Cell survival assay (limited dilution assay). The survival assay was
performed as described previously (20) with some modifications.
Briefly, cells were plated in 96-well plates, incubated with imexon for
48 hours and exposed to 1, 2.5, or 5 Gy of radiation (γ-rays, using a
137Cs source, dose rate 3.7 Gy/min). To test the influence of treatment
sequence, additional assays were performed where imexon was added
immediately after radiation, or 6 hours after radiation, and maintained
for 48 hours. Immediately after radiation, the cells were harvested,
plated into 96-well plates and maintained for 14 days in normal growth
medium to determine cell growth. Survival was calculated by an
adaptation of the estimation of the 50% endpoint between live and
dead cells (21). After 14 days, lymphoma cells were stained with MTT
and wells with live cells were scored and the quantitative data were
fitted by a logistic regression to determine the number of cells needed
to achieve growth in 50% of the wells at the respective dose level
(D50). The survival fraction at a given dose was calculated as a ratio of
D50 of irradiated cells and D50 of unirradiated, control cells. Survival
curves were constructed from at least three independent experiments
by fitting the average survival levels.
Glutathione (GSH) assay. Intracellular reduced GSH was assayed
in H9 cells by ortho-phthalaldehyde (OPA) staining procedure and
the intensity was measured using a fluorometer, as described
previously (22) with some modifications. Briefly, cells were washed
with ice-cold phosphate-buffered saline (PBS) and resuspended in
ice-cold lysis buffer (5% TCA, 1 mM EDTA, and 0.1 M HCl at
1:1:1, v/v/v ratio). The insoluble materials were removed by
centrifugation. GSH measurement was carried out by mixing 0.2 ml
lysates with 3.6 ml 0.1 M phosphate/5 mM EDTA buffer (pH 8.0)
and 0.2 ml OPA stock (1 mg ml–1 ethanol). Fluorescence was
measured at 420 nm (emission) with 350 nm excitation wavelength.
A standard curve was constructed using known amount of GSH and
used for obtaining the GSH levels in the lysates.
Apoptosis and cell cycle distribution. H9 Cells were subjected to
TUNEL [terminal deoxynucleotidyl-transferase (TdT) dUTP nick-
end labeling] assay and stained with propidium iodide after 48-hour
imexon (40 μM) incubation and/or radiation (5 Gy). Apo-direct kit
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Figure 1. In vitro proliferation assay in H9 cells. Cells were plated in
96-well plates, then 24 hours later treated with increasing doses of
imexon (10-160 μM) and incubated for 48 hours. Cells were then stained
with MTT and lysed, and the absorbency was read in a plate reader
using a 540-nm filter. Viable cells were calculated as percentage of the
control. Data shown are mean±SE from three independent experiments.
(BDPharmingen, San Diego, CA, USA) was used following the
manufacturer’s protocol to quantify the apoptotic cells. The
significance of data on apoptosis was analyzed by Student’s t-test
and p-value equal to or below 0.05 was considered as significant. 
Western blot analysis. Cells were treated with imexon and/or
radiation (5 Gy). Cell lysates were obtained at various time points
and subjected to Western blot analysis as described (23). Primary
antibodies were bought from Abcam Inc. (Cambridge, MA, USA)
and secondary antibodies were bought from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The immunoreaction
was visualized by ECL plus detection system (Amersham, Arlington
Heights, IL, USA) and analyzed using ImageQuant software and
Typhoon scanning system (Molecular Dynamics Inc. CA, USA).
Results
Enhancement of radiosensitivity by imexon. Firstly, the
antiproliferative effect of imexon, given as a single agent, in
H9 cells was determined. Imexon reduced cell proliferation and
the effect was dose dependent (Figure 1). A 40% reduction in
cell proliferation was observed at the dose of 40 μM of
imexon. For further investigation we used 10 and 40 μM of
imexon. To determine whether imexon increases the sensitivity
of tumor cells to radiation, in vitro cell survival was assayed.
H9 and Raji cells were exposed to 10 or 40 μM imexon for 48
h and then exposed to increasing doses of radiation (1, 2.5 or 5
Gy). Whereas 10 μM imexon had no effect on cells
radiosensitivity (data not shown), 40 μM imexon potently
enhanced the radiosensitivity of both the cell lines tested.
Figure 2 shows the radiation dose-response curves for H9 and
Raji cells. The curves representing the effect of imexon plus
radiation were normalized against drug effect. Radiation itself
caused a dose-dependent reduction in cell survival.
Pretreatment with imexon efficiently enhanced radiosensitivity
that was apparent by the shifting of survival curves to left.
Radiosensitivity enhancement factors (EFs) were calculated by
dividing the radiation dose of the control curve by that of the
corresponding imexon plus radiation curves at 0.1 survival
fraction. In both cell lines, radiation enhancement was
significant (p-values Student’s t-test <0.05): the EF was 2.2 in
H9 cells and 1.6 in Raji cells. To investigate whether
radiosensitization by imexon was possible if imexon was
applied after radiation, additional cell survival assays were
performed, where imexon was added immediately after
radiation or after a 6-hour time span and incubation was
continued for 48 hours. Imexon did not induce radiation
enhancement in either experimental set-up (data not shown). 
Induction of apoptosis. Apoptosis is an important mechanism
of cell death in hematological malignancies. To investigate
whether the combined effect of imexon and radiation was
due to increased apoptosis, H9 cells were subjected to
TUNEL assay. Since 40 μM of imexon was effective in
enhancing cell radiosensitivity, induction of apoptosis was
tested after exposing the cells to 5 Gy of radiation, 40 μM
of imexon for 48 hours, or both where cells were first
exposed to imexon for 48 hours prior to irradiation. Cells
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Figure 2. In vitro cell survival assay (limited dilution assay) of H9 (A) and Raji (B) cells. Cells were pre-incubated with 40 μM imexon for 48 hours
and then irradiated. Immediately after irradiation, cells were trypsinized, plated in 96-well plates and allowed to grow for 14 days. Wells that were
positive for lymphoma cells were scored and the quantitative data were fitted by a logistic regression to determine the number of cells needed to
achieve growth in 50% of the wells at the respective dose level (D50). The survival fraction at a given dose was calculated as a ratio of D50 of
irradiated cells and D50 of unirradiated, control cells. Survival curves were constructed with normalized values for the cytotoxicity induced by
imexon alone. Values shown are the means±SE for three independent experiments.
were assayed 24 hours after irradiation. Imexon and 5 Gy
when given as single agents induced apoptosis by 13.6±5%
and 9.6±4.2%, respectively. When these two agents were
combined, the induction of apoptosis was supra-additive,
55.2±9.8% (Figure 3A, B). 
Western blot analysis. To determine alterations in cellular
proteins that are involved in apoptosis, whole cell lysates of
H9 cells were prepared after imexon (40 μM, 48 hours) and
radiation treatment and were subjected to Western blot
analysis. Imexon or 5 Gy as single agent induced cleavage of
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Figure 3. Induction of apoptosis by imexon and radiation in H9 cells. Cells were pre-incubated with 40 μM imexon for 48 hours before exposing them
to a single dose irradiation (5 Gy). Cells were subjected to TUNEL assay 24 hours after irradiation. A, Flow cytometric analysis of apoptotic cells.
Data are representative of three independent experiments. B, Quantitative data on apoptosis induced by imexon and radiation from three independent
experiments (mean±SE). * Significant supra-additive effect of combined treatment (Student’s t-test, p≤0.05). C, Western blot analysis for the
expression levels of cleaved caspase 3 and PARP. Cells were lysed at specific time points shown in the figure after treatments with imexon, radiation
or both. Whole cell lysates were subjected to Western blot analysis. Representative blots of three independent experiments are shown.
caspase-3, which was significantly enhanced when both
treatments were combined (Figure 3C). To investigate if
apoptosis induction was mediated via mitochondrial (caspase-
9) or death receptor (caspase-8) pathway, we performed
Western blotting against cleaved caspase-9 and caspase-8. A
moderate increase in cleaved caspase-9 was observed after
imexon (48 hours) treatment. Exposure of cells to 5 Gy and
analysis of cell lysates 6 hours after irradiation showed a slight
Cho et al: Imexon Augments Cell Radiosensitivity
4413
Figure 4. Cell cycle redistribution in H9 cells. A, Cells were exposed to imexon, radiation (5 Gy), or both, then fixed and stained with propidium
iodide (DNA-stain)/RNase solution and analyzed by flow cytometry. Data shown are means±SE of three independent experiments. B, Representative
cell cycle analysis after imexon, radiation, or both. Imexon caused accumulation of H9 cells in the radiosensitive G2 phase of the cell cycle while
reducing the number of cells in the G1 and S phases.
increase in cleaved caspase-9 protein; however, combined
treatment with imexon and irradiation failed to induce
caspase-9 cleavage at the time points tested. H9 cells did not
show any measurable amount of caspase-8 (data not shown).
Effect on the cell cycle. Previous reports indicated that
imexon affects the cell cycle distribution of myeloma cell
lines at low doses. Because the cell cycle distribution has an
effect on radiation sensitivity, we performed cell cycle
analysis after 48 hours of incubation with imexon±radiation.
As shown in Figure 4, imexon caused H9 cells to accumulate
in the radiosensitive G2 phase of the cell cycle while
reducing the number of cells in G1 and S phases. 
Effect on cellular redox status. Previous studies link the pro-
apoptotic effect of imexon in myeloma cell lines to
modulation of the cellular redox status; however, high
concentrations of imexon were used in these studies (>90 μM)
(11-13). To investigate whether radiosensitization by imexon
in H9 cells was mediated by alterations in cellular redox
status, we assessed reduced GSH levels after exposing the
cells to imexon (40 μM) for 48 hours, after radiation, or after
both. Imexon slightly reduced the GSH level in H9 cells but
this effect was not significant (data not shown). 
Discussion
In this study, we explored the efficacy of imexon at enhancing
the sensitivity of H9 cells and Raji cells to radiation. We found
that both lymphoma cell lines were sensitive to imexon in a
dose range that is comparable to myeloma cell lines investigated
in other reports (IC50 below 50 μM) (14). Our study showed
that enhancement of radiosensitivity in H9 cells by imexon was
dependent on the sequence of administration. The greatest
extent of radiosensitization was achieved when imexon was
given for 48 hours before the radiation. It is interesting to note
that imexon was not effective in enhancing radioresponse when
given after radiation. Pretreatment with imexon accumulated
cells in the G2 phase, a radiosensitive phase of the cell cycle
(24). Thus, imexon may have increased the susceptibility of
cells to radiation-induced cell death. The cellular redox system
has been demonstrated to be involved in cellular resistance of
hematological malignancies (25-28). One line of evidence
indicates that imexon-induced apoptosis correlates with
formation of reactive oxygen species, depletion of thiols and
mitochondrial alterations at high concentrations between 90 and
500 μM in several studies (11, 12, 14, 15). GSH is a non-protein
cellular thiol that is a critical component to cellular oxidative
stress (29, 30) and has been found to sensitize tumor cells to
oxidative cytolysis (31-33). Evens et al. (14) suggested that
imexon-induced apoptosis is independent of ROS production
and thiol depletion at low dose levels (80-160 μM). In their
study using various dexamethasone and chemotherapy-sensitive
and -resistant myeloma cell lines, significant ROS production
and thiol depletion occurred only at imexon concentrations
>300 μM after 48 hours incubation and they did not correlate
with apoptosis. Consistent with this study, our data showed no
significant thiol depletion after 40 μM of imexon treatment in
the lymphoma cells. It is important to note that in the
aforementioned study (14), imexon exhibited its effect on
refractory lymphoma cells.
Apoptosis is induced either by intrinsic or extrinsic
pathway (34). Dvorakova et al. (3) reported that imexon-
induced redox regulation activates the intrinsic or
mitochondrial pathway of apoptosis involving cytochrome c
release and activation of caspase-9 and -3. Caspase-9 has
been proposed as the major caspase in the mitochondrial
pathway of apoptosis that is death receptor independent.
Evens et al. (14) described increasing proapoptotic bax
expression and alteration of the bcl-2/bax ratio after treatment
with low doses of imexon. Furthermore, they showed that in
some myeloma cell lines, imexon-induced apoptosis was
caspase-8 dependent. Our data showed that imexon activated
caspase-9 and -3, while activation of caspase-8 was not
observed, suggesting that imexon predominantly initiated the
intrinsic, mitochondrial pathway of caspases in H9 cells. 
Therapeutic implications for the treatment of lymphoma are
that imexon could be effective in malignant lymphoma that
lacks receptor for the activation of apoptosis (3). In a recent
clinical phase 1 dose escalation trial in patients with advanced
malignancies, grade 3 abdominal pain and fatigue, and grade
4 neutropenia were observed as dose-limiting toxicities of
imexon (35); interestingly, a decrease in plasma thiol levels
did correlate with imexon exposure. Our study presents
evidence that 40 μM imexon, which is non-toxic and clinically
achievable, can be combined with radiotherapy to improve the
treatment outcome. In conclusion, our in vitro data presented
here show that imexon potently enhanced the radiosensitivity
of H9 and Raji cells, and the underlying mechanisms may
include apoptosis and cell cycle redistribution. These data
suggest that imexon has the potential to increase the
radioresponse of malignant lymphoma and warrants further
investigation using in vivo tumor models.
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